Rodman David Malcom 4

What Happened
Rodman Malcom, Chief Medical Officer of Mineralys Therapeutics, exercised stock options to acquire 2,171 shares at $16.00 per share (cost $34,736) and immediately sold those 2,171 shares in the open market at $26.84 per share for proceeds of $58,270 on March 9, 2026. The transactions were reported on a Form 4 filed March 10, 2026. The net pre-tax cash difference between sale proceeds and exercise cost is roughly $23,534.

Key Details

• Transaction date: 2026-03-09; Form 4 filed: 2026-03-10 (timely filing).
• Option exercise: 2,171 shares acquired at $16.00 each = $34,736 (Code M).
• Open-market sale: 2,171 shares sold at $26.84 each = $58,270 (Code S).
• A related derivative line is reported at $0 (reflects the option conversion/settlement).
• Transactions were effected pursuant to a Rule 10b5-1 trading plan adopted October 6, 2025 (Footnote F1).
• Vesting: the option vested 25% after one year, remainder over 36 monthly installments (Footnote F2).
• Shares owned after the transactions are not specified in the provided excerpt of the filing.

Context
This was an exercise followed by an immediate sale — often a routine way for insiders to monetize vested options. The use of a pre-established 10b5-1 plan means the trades were executed according to a previously adopted schedule, which reduces the likelihood they were based on recent, nonpublic information. The filing does not indicate any late reporting or that Malcom is a >10% owner.